Novabay Pharmaceuticals Stock Performance

NBY Stock  USD 0.54  0.02  3.85%   
NovaBay Pharmaceuticals holds a performance score of 4 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 4.94, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NovaBay Pharmaceuticals will likely underperform. Use NovaBay Pharmaceuticals sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to analyze future returns on NovaBay Pharmaceuticals.

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in NovaBay Pharmaceuticals are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental drivers, NovaBay Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Forward Dividend Yield
0.339
Last Split Factor
1:35
Dividend Date
2025-09-29
Ex Dividend Date
2025-09-30
Last Split Date
2024-05-31
1
NovaBay Pharmaceuticals Shares Gap Down - Heres Why - MarketBeat
12/23/2025
2
NovaBay Pharmaceuticals Shares Down 6.8 percent - Should You Sell - MarketBeat
12/29/2025
3
NovaBay Pharmaceuticals Stock Price Up 14.2 percent - Should You Buy - MarketBeat
01/05/2026
4
Novabay Pharmaceuticals stock hits 52-week high at 11.49 USD By Investing.com - Investing.com India
01/09/2026
5
NovaBay Pharmaceuticals Stock Why Shares Exploded 103 percent on Friday
01/12/2026
6
NovaBay Pharma Secures Crypto-Focused Financing, Shifts Strategy - TipRanks
01/16/2026
7
NovaBay Pharmaceuticals Stock Price Down 14.3 percent - Should You Sell - MarketBeat
01/21/2026
8
Acquisition by David Lazar of 6388000 shares of NovaBay Pharmaceuticals subject to Rule 16b-3
01/29/2026
9
NovaBay Pharma Schedules Special Shareholder Meeting on Warrants - TipRanks
01/30/2026
Begin Period Cash Flow2.9 M
Total Cashflows From Investing Activities1.1 M

NovaBay Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  99.00  in NovaBay Pharmaceuticals on November 20, 2025 and sell it today you would lose (45.00) from holding NovaBay Pharmaceuticals or give up 45.45% of portfolio value over 90 days. NovaBay Pharmaceuticals is generating 1.4254% of daily returns assuming volatility of 23.7615% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than NovaBay, and most equities are expected to generate higher returns over the next 90 days.
  Expected Return   
       Risk  
Considering the 90-day investment horizon NovaBay Pharmaceuticals is expected to generate 31.38 times more return on investment than the market. However, the company is 31.38 times more volatile than its market benchmark. It trades about 0.06 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.18 per unit of risk.

NovaBay Pharmaceuticals Target Price Odds to finish over Current Price

The tendency of NovaBay Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.54 90 days 0.54 
about 78.83
Based on a normal probability distribution, the odds of NovaBay Pharmaceuticals to move above the current price in 90 days from now is about 78.83 (This NovaBay Pharmaceuticals probability density function shows the probability of NovaBay Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon the stock has the beta coefficient of 4.94 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, NovaBay Pharmaceuticals will likely underperform. Additionally NovaBay Pharmaceuticals has an alpha of 0.9446, implying that it can generate a 0.94 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   NovaBay Pharmaceuticals Price Density   
       Price  

Predictive Modules for NovaBay Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NovaBay Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.030.6824.24
Details
Intrinsic
Valuation
LowRealHigh
0.030.6924.25
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.000.000.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as NovaBay Pharmaceuticals. Your research has to be compared to or analyzed against NovaBay Pharmaceuticals' peers to derive any actionable benefits. When done correctly, NovaBay Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. NovaBay Pharmaceuticals is not an exception. The market had few large corrections towards the NovaBay Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NovaBay Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NovaBay Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.94
β
Beta against Dow Jones4.94
σ
Overall volatility
4.11
Ir
Information ratio 0.05

NovaBay Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NovaBay Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NovaBay Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
NovaBay Pharmaceuticals is way too risky over 90 days horizon
NovaBay Pharmaceuticals has some characteristics of a very speculative penny stock
NovaBay Pharmaceuticals appears to be risky and price may revert if volatility continues
NovaBay Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the last year's revenue of 9.78 M. Reported Net Loss for the year was (7.21 M) with profit before taxes, overhead, and interest of 6.52 M.
NovaBay Pharmaceuticals has about 430 K in cash with (5.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07.
Roughly 92.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: NovaBay Pharma Schedules Special Shareholder Meeting on Warrants - TipRanks

NovaBay Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NovaBay Stock often depends not only on the future outlook of the current and potential NovaBay Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NovaBay Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding3.4 M
Cash And Short Term Investments430 K

NovaBay Pharmaceuticals Fundamentals Growth

NovaBay Stock prices reflect investors' perceptions of the future prospects and financial health of NovaBay Pharmaceuticals, and NovaBay Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NovaBay Stock performance.

About NovaBay Pharmaceuticals Performance

Evaluating NovaBay Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NovaBay Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NovaBay Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 97.31  92.44 
Return On Tangible Assets(2.43)(2.31)
Return On Capital Employed(11.58)(11.00)
Return On Assets(2.43)(2.31)
Return On Equity 50.39  52.91 

Things to note about NovaBay Pharmaceuticals performance evaluation

Checking the ongoing alerts about NovaBay Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NovaBay Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
NovaBay Pharmaceuticals is way too risky over 90 days horizon
NovaBay Pharmaceuticals has some characteristics of a very speculative penny stock
NovaBay Pharmaceuticals appears to be risky and price may revert if volatility continues
NovaBay Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the last year's revenue of 9.78 M. Reported Net Loss for the year was (7.21 M) with profit before taxes, overhead, and interest of 6.52 M.
NovaBay Pharmaceuticals has about 430 K in cash with (5.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07.
Roughly 92.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: NovaBay Pharma Schedules Special Shareholder Meeting on Warrants - TipRanks
Evaluating NovaBay Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate NovaBay Pharmaceuticals' stock performance include:
  • Analyzing NovaBay Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NovaBay Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining NovaBay Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating NovaBay Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NovaBay Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of NovaBay Pharmaceuticals' stock. These opinions can provide insight into NovaBay Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating NovaBay Pharmaceuticals' stock performance is not an exact science, and many factors can impact NovaBay Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.